shox2 polyclonal antibody (Bioss)
Structured Review

Shox2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shox2 polyclonal antibody/product/Bioss
Average 90 stars, based on 2 article reviews
Images
1) Product Images from "NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules"
Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules
Journal: Oxidative Medicine and Cellular Longevity
doi: 10.1155/2022/8488269
Figure Legend Snippet: siRNA target sequences.
Techniques Used: Sequencing
Figure Legend Snippet: RT-qPCR primers.
Techniques Used:
Figure Legend Snippet: YXFMs thwart CACNA1G reduction within SSS mice SAN. (a) Immunofluorescence staining assay for VSNL1 and CACNA1G (scale = 20 μ m). (b) Western blotting assay for SHOX2. (c, d) Comparative analyses for Western blotting results and fluorescence intensities. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the SSS group. CON: control group; SSS: sick sinus syndrome group; YXFMs: Yixin-Fumai granule-administered group.
Techniques Used: Immunofluorescence, Staining, Western Blot, Fluorescence
Figure Legend Snippet: YXFMs activated NRF-2 and improve SHOX2 deficiency in senescent HL-1 cells. (a) DCFH-DA staining for ROS assay (scale = 50 μ m). (b) Immunofluorescence staining for NRF-2 and SHOX2 assay (scale = 10 μ m). (c) Comparative analyses for ROS content. (d) Comparative analyses for the NRF-2 and SHOX2 expression. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the CON group, ## P < 0.01 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group. CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + ML385: D-galactose + Yixin-Fumai granule + NRF-2 inhibitor ML385-administered group; H 2 O 2 : hydrogen peroxide-administered group.
Techniques Used: Staining, ROS Assay, Immunofluorescence, Expressing
Figure Legend Snippet: YXFMs improve pulsatile dysfunction in senescent hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Comparative analyses for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + si-NC: D-galactose + Yixin-Fumai granule-administered + si- NC transfection group; YXFMs + si- SHOX2 : D-galactose + Yixin-Fumai granule-administered + si- SHOX2 transfection group; YXFMs + ML385: D-galactose + Yixin-Fumai granules + NRF2 inhibitor ML385-administered group.
Techniques Used: Transfection
Figure Legend Snippet: YXFMs improve pulsatile function in SHOX2-silenced hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Statistical results for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- SHOX2 group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- SHOX2 : si- SHOX2 transfection group; YXFMs: si- SHOX2 transfection + Yixin-Fumai granule-administered group; SB4: si- SHOX2 transfection + BMP4 activator SB4-administered group; YXFMs + LDN193189: si- SHOX2 transfection + Yixin-Fumai granule + BMP4 inhibitor LDN193189-administered group. YXFMs + mibefradil: si- SHOX2 transfection + Yixin-Fumai granule + T-type calcium channel inhibitor mibefradil-administered group.
Techniques Used: Transfection
Figure Legend Snippet: YXFMs increase CACNA1G expression through SHOX2 upregulation. (a) CACNA1G expression in HL-1 cells (scale = 10 μ m). (b) Comparative analyses for RT-qPCR. (c) Comparative analyses for immunofluorescence staining. (d) Western blotting assay for SHOX2, BMP4, GATA4, and NKX2-5 in HL-1 cells. (e) Comparative analyses for Western blotting. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- Shox2 group. NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- Shox2 : si- Shox2 transfection group; YXFMs: si- Shox2 transfection + Yixin-Fumai granule-administered group; SB4: si- Shox2 transfection + BMP4 activator SB4-administered group.
Techniques Used: Expressing, Quantitative RT-PCR, Immunofluorescence, Staining, Western Blot, Transfection
Figure Legend Snippet: The mechanism of YXFMs improving SAN dysfunction: NRF-2/HO-1 pathway-mediated SHOX2 activation is a key switch.
Techniques Used: Activation Assay

